This week at the 84th Scientific Sessions of the American Diabetes Association conference, we will present new data: • Reaffirming the benefits of #DexcomCGM for people with Type 1, Type 2, and prediabetes. • Demonstrating improved outcomes for people with Type 2 diabetes, including those using #DexcomCGM in combination with GLP-1s. Dexcom also continues our leadership in product innovation and connectivity with the Dexcom G7 and Omnipod 5 Automated Insulin Delivery System integration, and multiple Dexcom G7 app updates, including Direct to Apple Watch. Learn more about our presence at #ADA2024 [link here: https://lnkd.in/g_JXz4xu] And for those attending ADA this year, visit the 𝐃𝐞𝐱𝐜𝐨𝐦 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐄𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐌𝐢𝐜𝐫𝐨𝐬𝐢𝐭𝐞 for program information [link here: https://lnkd.in/ge5MPxDF]
Alan K.
2mo
Everyone at risk of diabetes should have access to a CGM. Next stop, those that test positive for dual antibodies in a Type 1 diabetes screening. Let’s go!
Julian M.
2mo
Thank you for all you are doing to provide an improved quality of life, with people close saying the Dexcom solutions they use give them hope and improved data to help them in their daily lives.
Neil Williams
2mo
I use G7 with Tandem and Apple Watch + iPhone. Brilliant - thanks Dexcom.
Loving the direct to Apple Watch
Hi Are you looking for Diabetes Dexom sales reps?
Looking forward to this!
Lisa Edmonds
2mo
Are you looking for Diabetes Dexom sales reps?
Awesome innovation!
Assistant Clinical Research Coordinator & Diabetes Researcher at Stanford Medicine
2moThis is amazing! Your devices have been life-changing for me, so I am happy you are expanding access to your devices to people with type 2 diabetes as well.